Search hospitals > New York > Commack
Memorial Sloan Kettering Commack
Claim this profileCommack, New York 11725
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Pancreatic Cancer
Conducts research for Lymphoma
682 reported clinical trials
190 medical researchers
Summary
Memorial Sloan Kettering Commack is a medical facility located in Commack, New York. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Pancreatic Cancer, Lymphoma and other specialties. Memorial Sloan Kettering Commack is involved with conducting 682 clinical trials across 610 conditions. There are 190 research doctors associated with this hospital, such as Christopher J. Forlenza, Thomas Kaley, MD, Alan L Ho, MD, PhD, and Andrea Cercek, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 positive
HER2 negative
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Christopher J. ForlenzaMemorial Sloan Kettering Cancer Center8 years of reported clinical research
Expert in Langerhans Cell Histiocytosis
Expert in Neuroblastoma
18 reported clinical trials
38 drugs studied
Thomas Kaley, MDMemorial Sloan Kettering Cancer Center7 years of reported clinical research
Expert in Brain Tumor
Studies Glioblastoma
15 reported clinical trials
23 drugs studied
Alan L Ho, MD, PhDMemorial Sloan Kettering Cancer Center1 year of reported clinical research
Studies Thyroid Cancer
Studies Salivary Gland Cancer
16 reported clinical trials
26 drugs studied
Andrea Cercek, MDMemorial Sloan Kettering Cancer Center2 years of reported clinical research
Studies Colorectal Cancer
Studies Rectal Cancer
15 reported clinical trials
32 drugs studied
Clinical Trials running at Memorial Sloan Kettering Commack
Lung Cancer
Breast Cancer
Skin Cancer
Ovarian Cancer
Cervical Cancer
Bladder Cancer
Brain Tumor
Oropharyngeal Carcinoma
Prostate Cancer
Colorectal Cancer
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Proton Craniospinal Radiation
for Cancer in the Brain and Spinal Cord
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.
Recruiting2 awards Phase 33 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Memorial Sloan Kettering Commack?
Memorial Sloan Kettering Commack is a medical facility located in Commack, New York. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Pancreatic Cancer, Lymphoma and other specialties. Memorial Sloan Kettering Commack is involved with conducting 682 clinical trials across 610 conditions. There are 190 research doctors associated with this hospital, such as Christopher J. Forlenza, Thomas Kaley, MD, Alan L Ho, MD, PhD, and Andrea Cercek, MD.
Where is Memorial Sloan Kettering Commack located?
Memorial Sloan Kettering Commack is situated at 650 Commack Road, Commack, NY 11725. Access is convenient via the Long Island Expressway (I-495), taking Exit 53 and proceeding north on Commack Road, where the hospital is located on the right side.
Who should I call to ask about financial aid or insurance network?
**Memorial Sloan Kettering Commack Hospital Contact Information:**
- **Financial Assistance:** Call Patient Financial Services at 212-639-3810 or visit a representative at:
- Rockefeller Outpatient Pavilion, 160 East 53rd Street, 3rd floor
- 64th Street Outpatient Center, 205 East 64th Street, Lower Concourse
- Evelyn H. Lauder Breast Center, 300 East 66th Street, 1st Floor
- The Sidney Kimmel Center for Prostate and Urologic Cancers, 353 East 68th Street, 1st floor
- Main Hospital, 1275 York Ave, Room A104 (near the 67th Street entrance)
- **Insurance Questions:** Call Patient Billing Services at 646-497-9176 or email [billing@mskcc.org](mailto:billing@mskcc.org).
- **Prescription Assistance Programs:** Contact your doctor’s office to meet with your Patient Access Coordinator.
- **International Patients:** Call the International Center at 212-639-4900 or use AT&T Direct Access by dialing the access number for your country, then 888-675-7722.
- **General Inquiries:** Call 212-639-2000.
What insurance does Memorial Sloan Kettering Commack accept?
Memorial Sloan Kettering Cancer Center (MSK) accepts a variety of insurance plans, including but not limited to Medicare, Medicaid, and commercial plans from Aetna, Blue Cross Blue Shield, Cigna, and many others. It's important to verify that your specific plan includes MSK in its network by reviewing the list of participating insurance plans or contacting MSK directly. Patients are also encouraged to confirm their coverage and financial responsibility with their insurance company.
What awards or recognition has Memorial Sloan Kettering Commack received?
Memorial Sloan Kettering Cancer Center, including its Commack location, is celebrated for its pioneering research and exceptional patient care, emphasizing safety and innovative treatments. The center's scientists are recipients of prestigious awards, such as the Marie-Josée Kravis Women in Science Endeavor (Kravis WiSE) fellowship grants. It boasts one of the country's largest clinical trials programs for cancer, offering patients early access to the latest treatments.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.